跳转至内容
Merck
CN

Y0001493

呋塞米

European Pharmacopoeia (EP) Reference Standard

别名:

4-氯-N-呋喃基-5-氨磺酰邻氨基苯甲酸, 5-(氨基磺酰基)-4-氯-2-([2-呋喃甲基]氨基)苯甲酸

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C12H11ClN2O5S
CAS号:
分子量:
330.74
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

furosemide

制造商/商品名称

EDQM

mp

220 °C (dec.) (lit.)

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl

InChI

1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)

InChI key

ZZUFCTLCJUWOSV-UHFFFAOYSA-N

基因信息

human ... SLC12A1(6557)

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Furosemide for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

抑制肾脏中离子的协同运输。

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Health hazardExclamation mark

警示用语:

Danger

危险声明

危险分类

Acute Tox. 4 Oral - Repr. 1B

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Christianne L Roumie et al.
Stroke, 46(2), 465-470 (2015-01-01)
We examined blood pressure 1 year after stroke discharge and its association with treatment intensification. We examined the systolic blood pressure (SBP) stratified by discharge SBP (≤140, 141-160, or >160 mm Hg) among a national cohort of Veterans discharged after
Adam D DeVore et al.
European journal of heart failure, 17(3), 340-346 (2015-01-27)
Loop diuretics are a cornerstone of heart failure (HF) treatment, but data regarding diuretic dose adjustments after a HF hospitalization and the association with subsequent outcomes are limited. This study was therefore conducted to determine these factors. We analysed data
K M Ho et al.
Anaesthesia, 65(3), 283-293 (2010-01-21)
Furosemide, a potent loop diuretic, is frequently used in different stages of acute kidney injury, but its clinical roles remain uncertain. This review summarises the pharmacology of furosemide, its potential uses and side effects, and the evidence of its efficacy.
Kurt A Wargo et al.
The Annals of pharmacotherapy, 43(11), 1836-1847 (2009-10-22)
To review the literature regarding the pharmacokinetic profiles, comparative safety and efficacy, and comparative costs of loop diuretics to evaluate the current clinical usefulness of furosemide. A search of MEDLINE (1966-June 2009) was conducted using the terms furosemide, torsemide, bumetanide
Phillip J Newton et al.
Journal of pain and symptom management, 36(4), 424-441 (2008-05-13)
Dyspnea is a common and distressing symptom associated with multiple chronic illnesses and high levels of burden for individuals, their families and health care systems. The subjective nature dyspnea and a poor understanding of pathophysiological mechanisms challenge the clinician in

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门